NovoCure (NVCR) Stock Jumps 28% After Record Revenue and Raised Guidance
TLDR
- NovoCure reported record Q2 net revenue of $183.6 million, up 16% year over year
- Global active patients rose 18% to 5,128 across all TTFields indications
- Adjusted EBITDA turned positive at $10.8 million, versus a $10 million loss a year ago
- Full-year 2026 revenue guidance raised to $710M–$725M
- Optune Pax received CE Mark approval for locally advanced pancreatic cancer in Europe
NovoCure (NVCR) stock surged 28.39% after the company posted record quarterly revenue and lifted its full-year outlook, giving investors a lot to cheer about.
Q2 net revenue came in at $183.6 million, up 16% from the same period last year. That beat expectations and set a new quarterly record for the company.
Active patients on TTFields therapy worldwide grew 18% year over year to 5,128. Optune Gio remains the biggest driver with 4,636 active patients, while Optune Lua posted 51% growth to 207 patients.
Optune Pax, the pancreatic cancer indication launched in the U.S. earlier this year, generated 418 prescriptions in Q2. There were 285 active U.S. patients on therapy as of June 30.
… Continue reading the full article at the original source below.
